Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $74

Benzinga · 05/08 14:43
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $53 to $74.